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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To assess the diagnostic accuracy of rapid diagnostic tests (RDTs) for detecting P vivax malaria parasitaemia in people living in malaria-
endemic areas who present to ambulatory healthcare facilities with symptoms suggestive of malaria, and to identify which types and
brands of commercial tests best detect P vivax malaria.
B A C K G R O U N D
Target condition being diagnosed
Malaria is a life-threatening disease caused by Plasmodium species
(Plasmodium spp.), transmitted by the bite of a female Anopheles
mosquito. Currently, there are five established Plasmodium spp.
that causemalaria in humans. The twomost common arePlasmod-
ium falciparum andPlasmodium vivax. Vivax malaria is a relapsing
form, which is rarely fatal but can cause serious anaemia in chil-
dren (Abba 2014). There has been an increased focus on P vivax
as malaria-endemic settings that also have P falciparum have made
progress in P falciparum control. Outside Africa, P vivax is the
predominant Plasmodium spp. in the Americas, South-East Asia,
and the World Health Organization (WHO) Eastern Mediter-
ranean regions; causing 64%, greater than 30%, and greater than
40% of all malaria cases, respectively (WHO 2017a). People with
malaria caused by P vivax can have relapses due to the dormant
liver stage hypnozoites. People can carry hypnozoites ranging from
a few weeks to more than 12 months before reporting symptoms
again (Battle 2014). Primaquine is recommended additionally to
standard malaria treatment for P vivax and Plasmodium ovale to
clear these liver stage parasites. Due to this, it is important to have
diagnostic tests that are highly sensitive and specifically detect P
vivax from other Plasmodium spp.
Index test(s)
Rapid diagnostic tests (RDTs) (WHO 2003), detect parasite-spe-
cific antigens in a drop of fresh blood through lateral flow im-
munochromatography (WHO 2006). Generally, RDTs do not re-
quire a laboratory, any special equipment, or specialized training.
They are easy to use and can give results as a simple positive or
negative result, at thresholds pre-set by the manufacturers, within
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15 to 20 minutes (Talman 2007; WHO 2006). Therefore, RDTs
are, in general, suitable for remote areas with limited facilities and
lack of laboratory expertise. However, they have a limited shelf life
(24 months) and need to be kept dry and away from temperature
extremes (greater than 40°C). They may also fail to detect malaria
where there are low levels of Plasmodium parasites in the blood
and false positives are possible due to cross reactions with other
disease conditions, presence of certain immunological factors, and
gametocytaemia (Kakkilaya 2003).
There is strong evidence that storage conditions of the RDT affect
their performance (Moonasar 2007). The parasite density of the
blood sample can also affect the performance of the RDT. The
WHO malaria RDT product testing programme report investi-
gated the effect of parasite density by testing individual products
under laboratory conditions using standardized blood samples at
low and high parasite densities (200 and 2000 parasites/µL), and
reported the ‘panel detection score’ (WHO 2012). An existing
Cochrane Review on non-falciparum RDTs found that parasite
density and storage conditions are often poorly reported in field
studies (Abba 2014).Morever, due to the lag period betweenwhen
the RDT was evaluated by the WHO malaria RDT product test-
ing programme to when the RDT is actually used in the field,
manufacturers may have modified the RDT during this period.
Different types of RDT use different types of antibody or com-
bination of antibodies to detect Plasmodium antigens. Some an-
tibodies aim to detect a particular species while others are pan-
malarial, aiming to detect all types of Plasmodium. Currently, all
commercial RDTs specific for P vivax use P vivax-specific lactate
dehydrogenase (LDH) antigens (WHO 2017b).
Clinical pathway
People of any age with malaria typically present to medical care
with non-specific symptomsof fever, headache, chills, or rigor. The
RDTs are most commonly used at the point of presentation with
these symptoms, most often in settings where quality microscopy
is not available. Parasitological diagnosis is recommended prior to
commencing on any treatment (WHO 2015a).
Prior test(s)
It is unlikely that patients will have had previous testing for their
current infection prior to presentation to healthcare centres with
symptoms of malaria. One key benefit of RDTs is the ease of use at
point of care. For the purpose of this review, wewill not address the
sensitivity or specificity of P vivax-specific RDTs for confirming
efficacy of treatment as this is not recommended practice.
Role of index test(s)
Malaria is a common cause of fever in endemic regions. Given the
non-specific symptoms patients with malaria often present with,
a parasitological test is recommended to make a formal diagnosis
(WHO 2015b). Often people of any age or gender presenting to
a healthcare clinic with a history of fever in a malaria-endemic
region will undergo a malaria test as part of a routine initial work-
up. As such, the population receiving the index test would be iden-
tified solely on the basis of the clinical history and physical exam-
ination. RDTs have a role in malaria diagnosis where there is no
access to good quality microscopy services and in outbreak inves-
tigation or surveys of parasite prevalence. Reliable diagnosis of P
vivax malaria with RDTs would not only benefit the individual by
allowing treatment of the blood stage and latent hypnozoite stage,
but also would have benefits at a population level by potentially
reducing low-level ongoing transmission due to relapsing disease.
Widespread use of accurate RDTs can facilitate greater diagnosis
and treatment rates of P vivax malaria in areas where there is in-
adequate access to high-quality microscopy.
True positive results would allow effective treatment of active dis-
ease and facilitate prevention of relapse using drugs that target the
liver stage hypnozoites such as primaquine or tafenoquine, thus
effectively treating individuals and reducing the risk of onward
transmission. True negative results facilitate accurate diagnosis by
narrowing differential diagnoses of people presenting to care with
fever and non-specific symptoms. False positives would potentially
lead to over treatment of individuals with primaquine and either
chloroquine or artemisinin combination therapies. False negatives
would lead to potential relapsing disease and potentially ongoing
transmission at the population level.
Alternative test(s)
Microscopic examination of Giemsa-stained thick and thin blood
films remains the conventional laboratory method. Microscopic
examination has good sensitivity and specificity, and it allows
species and stage differentiations and quantification of parasites,
all of which are important in assessing disease severity, monitoring
response to treatment, and prescribing appropriate therapy. Inten-
sive examination is more likely to reveal parasitaemia so the test is
carried out with a fixed number of fields examined. Infections may
be missed if slides are not examined carefully (Wongsrichanalai
2007). Very low parasitaemia may be missed even by good qual-
ity microscopy; the limit of detection of thick smear microscopy
has been estimated at approximately 4 to 20 asexual parasites/
µL, although a threshold of 50 to 100 asexual parasites per µL
is more realistic under field conditions (Wongsrichanalai 2007).
False-positive results are also possible; if blood slides are not pre-
pared carefully, artefacts may be formed, which can be mistaken
for Plasmodium parasites (Wongsrichanalai 2007).
Polymerase chain reaction (PCR), which is a molecular method
based on DNA amplification, is the most accurate method of de-
tecting parasites in the blood. Compared to microscopy, PCR is
less prone to observer error and more sensitive at low levels of par-
asitaemia (Snounou 1993). For PCR, the limit of detection may
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be as low as 0.004 asexual parasites/µL (Hänscheid 2002). How-
ever, whether this increased ability to detect low level parasitaemia
makes it a better diagnostic test is uncertain, as submicroscopic
parasitaemia are of unknown clinical significance and the preva-
lence of asymptomatic submicroscopic infection is high in some
areas (May 1999). PCR is currently not widely available due to
logistical constraints and the need for specially-trained technicians
and a well-equipped laboratory. It is usually used only for research
purposes.
Rationale
P vivax is becoming increasingly important, especially in re-
gions targeting malaria elimination. In areas of co-endemicity, vi-
vax malaria is increasing proportionally compared to falciparum
malaria. Moreover, treatment for P vivax and Plasmodium ovale
malaria differs from other types of malaria. Therefore, it is impor-
tant the RDT can correctly identify P vivax from other species.
Geographically, P vivax has a much wider infection range com-
pared to otherPlasmodium spp and thismay increase over time due
to climate change (Culleton 2012). Historically, autochthonous
transmission of P vivaxwas happening in temperate climates, such
as England (Dobson 1994). An existing Cochrane Review assess-
ing RDTs for diagnosing uncomplicated non-falciparum malaria
was conducted in 2014 (Abba 2014). A subset of this review in-
cluded RDTs that diagnosed P vivax. This review will only assess
the diagnostic accuracy of RDTs that specifically detect P vivax
with vivax specific lactate dehydrogenase (LDH) antigens.
O B J E C T I V E S
To assess the diagnostic accuracy of rapid diagnostic tests (RDTs)
for detecting P vivax malaria parasitaemia in people living in
malaria-endemic areas who present to ambulatory healthcare fa-
cilities with symptoms suggestive of malaria, and to identify which
types and brands of commercial tests best detect P vivax malaria.
Secondary objectives
To assess the effect of transmission setting (perennial, seasonal,
or epidemic) and type of malaria present in the region on the
accuracy of RDTs for detecting P vivax malaria parasitaemia. We
will also assess the effect of different generations of an RDT on
test accuracy. For studies that used microscopy as the reference
standard, we will also assess the impact of level of training.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include retrospective or prospective cohort or cross-sec-
tional studies that assessed the accuracy of an RDT or compared
the accuracy of two or more RDTs in the same study population
(i.e. comparative accuracy studies). We will exclude case-control
studies because they are known to overestimate test accuracy and
we expect to find sufficient studies of a cross-sectional or cohort
design. Studies sampling a consecutive series of patients, or a ran-
domly selected series of patients are eligible. Where the report has
not explicitly stated that sampling was consecutive, but we judge
that consecutive sampling was most probable, we will include the
report. We will exclude studies if they did not present sufficient
data to allow us to extract or deduce the number of true positives,
false positives, false negatives, and true negatives (i.e. 2 x 2 data).
Participants
Studies recruiting people living inP vivax-endemic areas attending
ambulatory healthcare settings with symptoms of uncomplicated
malaria are eligible.
We will exclude studies if participants:
• were not immune to malaria had travelled from non-
malarious region to malarious regions, e.g. travellers or displaced
populations;
• had been previously treated for their current malaria
infection or the test was performed to assess whether treatment
was successful, or both;
• had symptoms of severe malaria as defined by the WHO
clinical definition (WHO 2014);
• did not have symptoms of malaria as defined by history of
fever, headache, or chills/rigor;
• were recruited through active case finding (for example,
door to door surveys).
In studies where only a subgroup of participants is eligible for
inclusion in the review, we will include the study provided that
we can extract relevant data specific to that subgroup. If studies
included some patients with severe malaria, and we cannot extract
data specific to the subgroup of participants with uncomplicated
malaria, we will include the study if 90% or more of the partici-
pants had uncomplicated malaria.
Index tests
Studies evaluating any immunochromatography-based RDT
specifically designed to detect P vivax malaria. We will only in-
clude RDTs that meet the WHO malaria RDT performance cri-
teria (WHO 2017b).
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Target conditions
Studies that aimed to detect P vivax malaria.
Reference standards
Studies are required to diagnose P vivax malaria using at least one
of the following two reference standards:
• conventional microscopy of thick blood smears and thin
blood smears. We will regard the presence of asexual parasites at
any density as a positive smear. Once the diagnosis is established
- usually by detecting parasites in the thick smear - the laboratory
technician can examine the thin smear to determine the malaria
species and the parasitaemia, or the percentage of the patient’s
red blood cells that are infected with malaria parasites. The thin
and thick smears are able to provide all three of these vital pieces
of information. Ideally, blood smears would be examined
independently and in duplicate with more than 100 high-power
fields;
• PCR, including quantitative PCR (qPCR), nested PCR
(nPCR), and real-time PCR (rPCR). We will also include studies
that use loop-mediated isothermal amplification (LAMP). Most
PCR-based assays for P vivax are only available as laboratory-
developed tests, which means they are rarely used clinically
outside of research projects where P vivax malaria is endemic.
They are especially useful for diagnosing asymptomatic people as
the assays have high sensitivity, particularly in samples with low
density of parasites. Molecular diagnostics theoretically have a
lower limit of detection than both RDTs and microscopy
depending on the training of microscopists and quality of
samples analysed. Significant variation exists between molecular
diagnostics developed including type of input material (DNA,
RNA, or whole blood), target gene, (number of ) species detected,
primer/probe composition and concentration, amplification
technique (PCR or isothermal), read-out (gel-electrophoresis,
fluorescence detection, lateral flow), and whether it is qualitative
or quantitative. However, no important differences have been
found in the accuracy of these tests (Roth 2016).
For studies that used both reference standards, we will extract 2
x 2 data for each reference standard and stratify the analyses by
reference standard.
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress).
Electronic searches
We will search the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register; Central Register of Controlled Trials
(CENTRAL), published in the Cochrane Library; MEDLINE
(PubMed); Embase (OVID); Science Citation Index Expanded
(SCI-EXPANDED) and Conference Proceedings Citation Index-
Science (CPCI-S), both in the Web of Science. We will adapt the
search terms for MEDLINE (PubMed) listed in Appendix 1 to
other electronic databases. We will report all search strategies in
full in the final review version.
Wewill also search theWHOInternational Clinical Trials Registry
Platform (WHO ICTRP; www.who.int/ictrp/en/) and Clinical-
Trials.gov (clinicaltrials.gov/ct2/home) for trials in progress, using
“vivax malaria”, “Plasmodium vivax”, and “rapid diagnostic test*”
or RDT* as search terms.
Searching other resources
We will check the reference lists of studies identified by the above
methods.
Data collection and analysis
Selection of studies
Two review authors (LC and SJ) will independently assess study
eligibility by examining the title and abstract of each article iden-
tified by the literature search and will exclude obviously irrelevant
studies. If either review author considers the abstract to be po-
tentially eligible, we will obtain the full-text article. Two review
authors will independently assess each full-text article against the
predefined inclusion and exclusion criteria, as discussed in the
‘Criteria for considering studies for this review’ section, and will
resolve any disagreements by discussion. If the review authors can-
not reach consensus, a third review author will have the final de-
cision. We will list all articles excluded after full-text assessment
and the reasons for exclusion in the Characteristics of excluded
studies’ table. We will illustrate the study selection process using
a PRISMA flow diagram.
Data extraction and management
Two review authors (LC and SJ) will independently extract data
using a pre designed data extraction form.
We will extract the following data.
• Authors, publication year, and journal.
• Study design.
• Study start date.
• Characteristics study participants (age, gender, co
morbidities, and pregnancy).
• Study inclusion/exclusion criteria.
• Study setting.
• Malaria species in study setting.
4Rapid diagnostic tests for Plasmodium vivax malaria in endemic countries (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Malaria prevalence and endemicity in study setting.
• Reference standard.
• Index test (brand name, target antigen, and batch numbers).
• Additional tests (and their results).
• RDT and reference standard setting.
• Lot testing of RDT used.
• Transport and storage conditions of RDTs.
• Training level of person performing index test.
• Training level of person performing reference standard (and
if available the WHO certified training level of the microscopist).
• Number of high power fields observed in microscopy.
• Parasite density of microscopy positive cases.
• Observers or repeats used.
• Number of indeterminate, missing or unavailable test
results.
• Number of true positives, false positives, false negatives,
and true negatives.
• Type of molecular amplification assay.
• Volume of blood samples.
• Limit of detection for PCR.
We will resolve any discrepancies in data extraction by discussion.
If needed, we will consult a third review author. We will contact
the authors of primary studies if we cannot resolve any disagree-
ments. In the event that this is unsuccessful, we will report the
disagreement in the review.
We will also report key study characteristics across studies in a
separate, additional table. These characteristics will include factors
which may affect the performance of RDTs (training level of per-
son performing the RDT, storage conditions, whether the RDT
used was lot-tested, and parasite density of microscopy-positive
cases).
Assessment of methodological quality
We will use the revised tool for the Quality Assessment of Diag-
nostic Accuracy Studies (QUADAS-2) to assess the risk of bias and
applicability of included studies (Whiting 2011).We have tailored
the tool to the context of the review as shown in Appendix 2. Two
review authors (LC and SJ) will independently assess methodolog-
ical quality using the tailored QUADAS-2 tool. We will resolve
any disagreements through consensus or by consulting a third re-
view author. We will use both graphics and text to summarize the
results.
Statistical analysis and data synthesis
We will stratify all analyses by the type of reference standard used.
We will perform preliminary analyses by plotting estimates of sen-
sitivity and specificity from the included studies on forest plots
and in receiver operating characteristic (ROC) space using the
software, Review Manager 5 (RevMan 5) (RevMan 2014).
If there are sufficient data, we will perform meta-analyses using
bivariate models to estimate and compare summary sensitivities
and specificities (summary points) (Chu 2006; Macaskill 2010;
Takwoingi 2015b).
To provide a coherent set of comparative analyses, we will group
studies according to commercial brand within each RDT type so
that in the primary test comparisonwemake comparisons between
RDT types and then between the brands of each RDT type sepa-
rately in secondary analyses. We will perform the test comparisons
using two analytic strategies: indirect and direct comparisons. In-
direct comparisons will be performed by using all available stud-
ies because comparative studies are known to be generally scarce
(Takwoingi 2013). However, indirect comparisons are prone to
bias due to confounding (Takwoingi 2013). Therefore, we will
also perform direct comparisons if comparative studies that make
head-to-head comparisons of brands or types in the same popu-
lation are available. We will compare test accuracy by including
covariate terms in bivariate models to estimate differences in sen-
sitivity and specificity. We will assess the statistical significance of
these differences by using likelihood ratio tests to compare models
with and without the covariate terms.
If analyses using bivariatemodels fail to converge due to sparse data
or few studies, we will simplify the models to univariate random
effects logistic regression models to pool sensitivity and specificity
separately (Takwoingi 2015a). We will perform meta-analyses us-
ing the meqrlogit command in Stata (STATA 2015).
Investigations of heterogeneity
Following preliminary investigations on forest and SROC plots,
if there are sufficient data, we plan to formally investigate hetero-
geneity by adding each potential source of heterogeneity as a co-
variate to a bivariate model (i.e. meta-regression).We plan to assess
the effect of transmission setting (perennial malaria, seasonal, or
epidemic) and type ofmalaria in region (vivax only, vivax and falci-
parum, mixed non-falciparum, or all types). To investigate the ef-
fect of different generations of an RDT as a result of modifications
made by a manufacturer, if explicit information is unavailable, we
will use study start date as a proxy and include it as a covariate in a
bivariate model. For studies that used microscopy as the reference
standard, we will assess the impact of level of training as defined
in conduct of the reference standard as according to QUADAS-2
(Appendix 2).
Sensitivity analyses
If there are sufficient data, we will perform sensitivity analyses to
examine the influence of risk of bias and study design (i.e. retro-
spective and prospective study designs on test accuracy). We will
examine the effect of including only studies that used a reference
standard that was likely to correctly classify the target condition
by excluding studies at high or unclear risk of bias from the main
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analyses. We will also assess the impact of including only studies
where participants received the same reference standard.
Assessment of the certainty of the evidence
Wewill assess the certainty of the evidence (i.e. quality of evidence
or confidence in effect estimates) using the GRADE approach
and GRADEpro Guideline Development Tool software (GRADE
2013; GRADEpro GDT 2015). In the context of a systematic re-
view, the ratings of the certainty of the evidence reflect the extent
of our confidence that the estimates of test accuracy are correct. As
recommended, we will rate the certainty of the evidence as either
high (not downgraded), moderate (downgraded by one level), low
(downgraded by two levels), or very low (downgraded by more
than two levels) for four domains: risk of bias, indirectness, in-
consistency, and imprecision. For sensitivity and specificity, the
certainty of the evidence will initially start as high when there are
high-quality cross-sectional or cohort studies that enrolled partic-
ipants with diagnostic uncertainty. If we find a reason for down-
grading the certainty of the evidence, we will classify the reason
as either serious (downgraded by one level) or very serious (down-
graded by two levels).
We will describe the implications of sensitivity and specificity in
terms of individual and population level for each of true positives.
Two review authors (LC and SJ) will discuss judgments and reach
a consensus. We will apply GRADE in the following way.
• Risk of bias: we will use QUADAS-2 to assess risk of bias.
• Indirectness: we will consider indirectness from the
perspective of test accuracy. We will use QUADAS-2 to assess
applicability concerns and look for important differences
between the populations studied (for example, in the
transmission intensity as defined by the WHO World Malaria
Report or WHO malaria country profiles for the corresponding
year), the setting, and the review question.
• Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity estimates.
We will carry out pre-specified analyses to investigate potential
sources of heterogeneity and will downgrade when we cannot
explain inconsistency in the accuracy estimates.
• Imprecision: we will consider the width of the confidence
intervals (CIs), and ask ourselves, “would we make a different
decision if the lower or upper limit of the 95% confidence
interval (CI) represented the truth?”. In addition, we will
calculate absolute numbers of true positives, false negatives, false
positives, and true negatives, as well as ranges for these values
based on the CIs of the pooled estimates of sensitivity and
specificity for various prevalences of vivax malaria; we will also
make judgements on imprecision using these calculations.
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A P P E N D I C E S
Appendix 1. Detailed search strategy
Search set MEDLINE (PubMed)
1 Malaria, vivax [MeSH]
2 Plasmodium vivax [MeSH]
3 “Plasmodium vivax” or “P vivax” or “vivax malaria” or “non-falciparum Malaria” Field: Title/Abstract
4 1 or 2 or 3
5 Exp Reagent kits, diagnostics [MeSH]
6 “Diagnostic Tests, Routine”[Mesh]
7 rapid diagnostic test* Field: Title/Abstract
8 RDT* Field: Title/Abstract
9 Dipstick* Field: Title/Abstract
10 “Rapid diagnostic device*” Field: Title/Abstract
11 MRDD Field: Title/Abstract
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(Continued)
12 OptiMal Field: Title/Abstract
13 “Binax NOW” or “NOW-ICT-Malaria” or “NOW-Malaria-ICT” Field: Title/Abstract
14 ParaSight or Parascreen or ParaHIT Field: Title/Abstract
15 “SD Bioline” or Carestart or Falcivax or Malascan Field: Title/Abstract
16 Immunochromatograph* or Immuno-chromatograph* Field: Title/Abstract
17 “Antigen detection” Field: Title/Abstract
18 “Rapid malaria antigen test*” Field: Title/Abstract
19 “Combo card test*” Field: Title/Abstract
20 Immunoassay [MeSH]
21 Chromatography [MeSH]
22 Enzyme-linked immunosorbent assay [MeSH]
23 “Rapid test*” Field: Title/Abstract
24 “Card test*” Field: Title/Abstract
25 Rapid AND (detection* or device* or test* or kit*) Field: Title/Abstract
26 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
27 4 and 26
Appendix 2. QUADAS-2 tool tailored to the context of the review
Domain Patient selection Index test Reference standard Flow and timing
Description Methods of patient se-
lection
How index






did not receive and
time interval between
index test or reference
standard
Signalling questions
(yes, no, or unclear)
Consecutive or random
sample of patients?
• ‘Yes’ if the study
Index test results inter-
preted without knowl-
edge of the results of ref-
PCR
PCR likely to correctly
classify the target condi-
Was there an appropriate
interval between index
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• ‘No’ if patients
were purposefully
selected, for example
based on previous test
results (such as using
Rapid diagnostic tests
(RDTs) only on those
who tested positive for
P vivax by microscopy/
PCR).
• ‘Unclear’ if the
study did not explicitly
state consecutive
enrolment or random

















Wewill answer this ques-
tion as ‘yes’ for all stud-
ies because PCR is an ob-
jective test with binary
outcomes. Thus, there
is no room for subjec-
tive interpretation of test
results or poor perfor-
mance of the test leading
to false negatives or false
positives
‘Yes’ if reference standard
was PCR.
Microscopy
Microscopy likely to cor-
rectly classify the target
condition?
‘Yes’ if microscopy was
performed for one sam-



















test and reference stan-
dard?
• ‘Yes’ if samples for
RDT and microscopy or
PCR were taken at the
same time. We felt this
was important given the
transient parasitaemia
associated with malaria.
• ‘No’ if the samples
for RDT and
microscopy or PCR




information on the time
interval.
Was a case-control de-
sign avoided?
This will always be
‘yes’ because case control




As the threshold is pre-
specified by the manu-
facturer in all RDTs, we
will answer this question
‘yes’ for all studies
Reference standard re-
sults interpreted without
knowledge of the results
of index test?
Wewill answer this ques-
tion ‘yes’ for all studies
using only PCR as the
reference standard be-
Did all patients receive a
reference standard?
• ‘Yes’ if all
participants received a
microscopy or PCR.
• ‘No’ if one or more
participants did not
receive microscopy or
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(Continued)
cause PCR is an objec-
tive test with binary out-
comes. Thus, there is no
room for subjective in-
terpretation of test re-
sults










• ‘Unclear’ if there is
insufficient information





PCR. Or if the reference
standard was applied
depending on index test
results
• ‘Unclear’ if there is
insufficient information
to determine whether or
not all patients received
microscopy/PCR.
Did the study avoid in-
appropriate exclusions?
• ‘Yes’ if no patients
were excluded after
inclusion in the study or
if exclusions are
adequately described.










given to make a
decision.
Did all patients receive
the same reference stan-
dard?
• We will answer this
question ‘yes’ if all
participants in the study
or a subset of





specified as a criterion
for inclusion in the
review.
• ‘No’ if participants
did not receive the same
reference standard.
• ‘Unclear’ if there is
insufficient information
to determine whether or
not all patients received
the same reference
standard.
Were all patients in-
cluded in the analysis?
• ‘Yes’ if the number
of participants in the
two-by-two table
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(Continued)
matches the number of
participants recruited
into the study or if
sufficient explanation
was provided for any
discrepancy.
• ‘No’ if some
participants recruited





given to make a
decision.
Risk of bias (high, low,
or unclear)
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation has intro-
duced bias?
Could the patient flow
have introduced bias?
Applicability concerns
(high, low, or unclear)
Are there concerns that
the included patients do
not match the review
question?
• ‘High’ if the
participants included in
the study lived in an
area with high




the study lived in an
area with low or very




to make a decision.
Are there concerns that
the index test, its con-
duct, or interpretation
differs from the review
question?
• ‘High’ if the study
describes inappropriate
storage conditions for
the index test, or if the
index test has not been
lot tested
• ‘Low’ if the study
describes suitable
storage conditions for
the index test that meet
manufacturer’s
requirements and if the
study has reported the




to make a decision
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
Wewill answer this ques-
tion ‘low’ for all stud-
ies because P vivax di-
agnosed by light mi-
croscopy or PCR does
match the review ques-
tion
Not applicable
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